Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 876 / https://doi.org/10.3332/ecancer.2018.876

Research

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study

Objectives: Cancer is frequently complicated by thromboembolic events (TEs). We aimed to determine the incidence of TEs in lung cancer patients treated with platinum-based chemotherapy and study patients’ baseline and treatment attributes correlating with its onset.

Materials and methods: Advanced lung cancer patients started on platinum-based chemotherapy were evaluated at baseline and during routine visits for the development of TEs. The duration of follow-up was 4 weeks from the last chemotherapy. A TE occurring between the first dose of chemotherapy and 4 weeks after the last dose was considered to be chemotherapy associated.

Results: Of the 165 patients on platinum chemotherapy who completed follow-up, TEs occurred in 4.8% (8 out of 165) patients. Among these, three patients had developed venous pulmonary thromboembolism and five patients had developed cerebral infarction, out of which four had arterial cerebral infarction and one patient had a superior sagittal sinus thrombosis. The majority of events (7 out of 8) occurred within 100 days of starting platinum chemotherapy. Overall, the median time until occurrence of TE was 48 days (range, 10–130 days). None of the presumed risk factors were found be associated with the occurrence of TEs on univariate analysis.

Conclusions: Advanced lung cancer patients on platinum chemotherapy are predisposed to thromboembolism due to many factors. Despite its lower incidence in our study, exclusion of patients with prior thrombosis suggests the incidence of de novo thrombosis, and hence raises a valid question of the need of thromboprophylaxis in a selected group of patients.

Keywords: Thromboembolic events (TEs), Platinum based chemotherapy, Lung cancer

Loading Article Metrics ... Please wait

Related articles

Review: Non-gastrointestinal stromal tumours soft tissue sarcomas: an update

Abstract | Full Article | PDF Published: 13 Aug 2019 / https://doi.org/10.3332/ecancer.2019.958

Clinical Study: Early toxicity and treatment outcomes of extended field-intensity modulated radiotherapy for cervical cancer patients with para-aortic nodal metastasis

Abstract | Full Article | PDF Published: 06 Aug 2019 / https://doi.org/10.3332/ecancer.2019.957

Research: Effect of radiation dose to the periventricular zone and subventricular zone on survival in anaplastic gliomas

Abstract | Full Article | PDF Published: 31 Jul 2019 / https://doi.org/10.3332/ecancer.2019.956

Research: Nurse-led renal cancer follow-up is safe and associated with high patient satisfaction—an audit from the East of England

Abstract | Full Article | PDF Published: 30 Jul 2019 / https://doi.org/10.3332/ecancer.2019.955

Case Report: Synchronous peritoneal carcinomatosis from a buccal squamous cell carcinoma: a case report focusing on possible metastatic mechanisms and novel therapeutic modalities

Abstract | Full Article | PDF Published: 29 Jul 2019 / https://doi.org/10.3332/ecancer.2019.954



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation